Abstract: A problem to be solved by the present invention is to provide a composition (1) for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting bone density reduction, the composition (1) including a culture supernatant or a processed product thereof, the culture supernatant being obtainable by culturing immune cells in the presence of lactic acid bacteria or a processed product thereof, or a composition (2) for inhibiting differentiation of osteoclast precursor cells into osteoclasts, improving bone metabolism, and/or inhibiting bone density reduction, the composition (2) including Lactobacillus plantarum strain L-137 (Lactobacillus plantarum L-137) or a processed product thereof. These compositions solve the problem.

Abstract: Provided herein is a medical infusion pump system that contains a pump and a reservoir containing an aqueous liquid pharmaceutical composition that is delivered to a subject by the pump and that contains an insulin compound at a concentration of 400 U/mL or more, ionic zinc and a non-ionic surfactant, and wherein the pump delivers the composition in pulses wherein the volume of the pulse is 0.5 ?L or less.

Abstract: Provided are a microorganism in which activity of a GNAT family N-acetyltransferase protein is weakened; a method for producing O-acetyl homoserine and L-methionine using the same; a composition for producing O-acetyl homoserine, the composition including the microorganism; and use of the microorganism for producing O-acetyl homoserine or L-methionine.

Abstract: The present invention generally relates to pharmacokinetic and pharmacodynamics markers for cancer therapeutic regimens and methods of treating cancer. Oncolytic virus probes that comprise a nucleic acid encoding soluble interferon beta (IFN?) and methods for use thereof are provided.

Abstract: Provided herein, are methods and compositions for detecting heteromeric protein complexes in biological samples. The methods and compositions allow for capturing and detecting the protein complex with substantially the same antibody, while avoiding detection of native proteins.

Abstract: The present invention relates to an extract of bacteria of the genus Sphingomonas, and compositions comprising an extract of bacteria of the genus Sphingomonas or at least one bacterium of the genus Sphingomonas for use in the prevention and/or the treatment of cutaneous reactions caused by an allergic reaction and for use in the modulation of the immune response and optionally in the reinforcement of the barrier function of the skin.

Abstract: The present invention is applied to the field of Biotechnology and Immunology and refers to combinations of immunogenic peptides, chimeric peptides, compositions that comprise them and the uses thereof for control of ticks, particularly ticks of the species Rhipicephalus microplus. The present invention further provides kits containing the combinations, chimeric peptides and/or compositions comprising the combinations of immunogenic peptides, and a method for inducing immune response in animals, particularly bovines.

Abstract: In one aspect the present invention is directed to mutant Neutrophil gelatinase-associated lipocalin (NGAL) proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract.

Abstract: The disclosure relates to a genetically engineered Z. mobilis ZM4 for producing PHB and uses thereof. A variety of strains capable of producing both PHB and ethanol that are constructed by integrating three codon-optimized essential genes for exogenous PUB biosynthesis, phaA, phaB and phaC, together with a tetracycline-inducible promoter Ptet into the genome of ZM4.

Abstract: An application of polyethylene glycol (PEG)-interferon and a protooncogene product targeting inhibitor in synergistic inhibition of tumors. Specifically, provided is use of an active ingredient combination. The active ingredient combination comprises PEG-interferon and a protooncogene product targeting inhibitor, and the combination is used for preparing a pharmaceutical composition for synergistic treatment of tumors. The active ingredient combination can synergistically inhibit the growth of tumors (especially lung, stomach, breast and liver cancers) effectively, and can significantly reduce toxic and side effects, and therefore can be widely used in targeted therapy of the tumors.

Abstract: A composition that includes tahina and probiotic bacteriais can be formulated for oral administration. The composition can also include at least one polyphenol originating in a plant other than sesame. The composition can be used in treatment of a neurodegenerative disease or disorder, such as Alzheimer's disease. A method for the preparation of the composition includes intimately mixing the tahina and the probiotic bacteria, while homogenizing without damaging the probiotic bacteria. The composition can be encapsulated within a pH-dependent enteric-coating polymer capable of protecting the mixture from gastric (stomach) acidity.

Abstract: A QA test slide for use in a stain QA method for a stain and method of making QA test slides are described. The QA test slide comprises: a transparent substrate; a piece of biopolymer material mounted on the transparent substrate; and a sticker defining an aperture and adhered to the transparent substrate over the piece of biopolymer material and with a portion of the piece of biopolymer material exposed by the aperture and wherein a machine readable code is borne by the sticker and the machine readable code encodes a unique identifier for the QA test slide.

Abstract: The present disclosure provides a gene combination for expressing and producing terrequinone A in Escherichia coli and use thereof. The gene combination includes a tdiAS gene, a tdiBS gene, a tdiCS gene, a tdiDS gene, a tdiES gene, an sfpS gene, an ScCKS gene, and an AtIPKS gene with nucleotide sequences set forth in SEQ ID NOS:1 to 8. In the present disclosure, a recombinant engineered strain capable of producing terrequinone A having anti-cancer activity is obtained by separately constructing recombinant plasmids pC02 and pU03 through the eight genes and transforming the two recombinant plasmids into E. coli. The content of terrequinone A in a fermentation broth thereof is 106.3 mg/L, which has potential application value in the biopharmaceutical field.

Abstract: A technique capable of achieving production of a biological material using photosynthetic microorganisms at low cost is provided. A method of producing a biological material includes culturing photosynthetic microorganisms in a culture medium containing dimethyl 2-oxoglutarate while the photosynthetic microorganisms are irradiated with light to cause the photosynthetic microorganisms to proliferate, and then collecting a substance produced by or accumulated in the photosynthetic microorganisms.

Abstract: The present invention provides a clostridial neurotoxin for use in a method of treating a brain disorder in a patient by promoting a neuroimmune response.

Abstract: The present application provides a protein heterodimer and use thereof. The protein heterodimer comprises a first polypeptide chain and a second polypeptide chain different from the first polypeptide chain, wherein the first polypeptide chain comprises IL12a, and the second polypeptide chain comprises interleukin-12b (IL12b). The protein heterodimer also comprises interleukin-2 (IL2) or its functional fragments, granulocyte macrophage colony stimulating factor (GMCSF) or its functional fragments, and one or more targeting moieties. The protein heterodimer can be used for the treatment of tumors.

Abstract: Provided are compositions and methods related to improved mucins, methods of making the improved mucins, and cells and cell cultures that express glycosylated mucins. The compositions and methods provide improved cell cultures, and improved methods of producing co-expressed proteins that are distinct from the mucins.

Abstract: The present invention provides isolated plasmids, recombinant microorganisms, kits, and methods for the treatment of inflammatory skin disease.

Abstract: The present invention relates to a composition comprising a Leuconostoc citreum strain or its culture as an active ingredient for preventing, improving or treating cholestatic liver injury, specifically primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). According to the present invention, since the composition exhibits excellent preventive and therapeutic effects on various cholestatic liver injuries, the composition can be usefully used as a composition for the treatment, prevention, improvement, or the like of cholestatic liver injury in humans or animals.

Abstract: Described herein are antigen-binding molecules that bind to bacteria (e.g., Listeria monocytogenes) and methods of use thereof. Also described herein are compositions and kits comprising these antigen-binding molecules.